delphistem Awarded NIH SBIR Phase I Grant

Today marks an important milestone for delphistem.

We are proud to share that delphistem has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Institutes of Health (NIH) to advance our regenerative medicine program for diabetes.

The award follows a competitive scientific peer-review process and provides federal funding to support the next stage of our research and development.

For our team, this milestone represents more than funding. It reflects years of scientific work toward a clear goal: developing a regenerative medicine approach designed to restore the body's natural ability to produce insulin.

The funding will allow us to continue advancing critical development work as we move our technology toward its next scientific milestones.

We're deeply grateful to our team, advisors, collaborators, investors, and everyone who has believed in what we're building.

There is still significant work ahead, but today we celebrate an important step forward.

About delphistem

delphistem is an Atlanta-based biotechnology company developing personalized regenerative medicine therapies with the goal of restoring natural function (not managing disease) with an initial focus on diabetes.